TOday’s Movers: Spark Therapeutics (NASDAQ:ONCE) Stock Rating Reconfirmed at Barclays; $77 Target Price Indicates 33.98 % Potential

August 9, 2018 - By Billy Entrekin

Spark Therapeutics, Inc. (NASDAQ:ONCE) Logo

Investors sentiment decreased to 1.19 in 2018 Q1. Its down 0.24, from 1.43 in 2017Q4. It dropped, as 21 investors sold Spark Therapeutics, Inc. shares while 42 reduced holdings. 33 funds opened positions while 42 raised stakes. 36.74 million shares or 2.75% more from 35.76 million shares in 2017Q4 were reported.

444,104 were accumulated by Macquarie Gru Ltd. Tocqueville Asset Mgmt L P reported 40,150 shares. Barclays Public Limited Company has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Clearbridge Limited Liability invested in 687,291 shares. Cwm Limited Com holds 120 shares or 0% of its portfolio. Lord Abbett & Ltd Liability reported 0.06% in Spark Therapeutics, Inc. (NASDAQ:ONCE). Savings Bank Of Montreal Can invested in 0% or 61 shares. State Street Corp holds 0.01% or 1.78M shares. Alps Advsrs reported 49,632 shares. California Employees Retirement owns 39,500 shares. Manufacturers Life Ins The owns 20,884 shares. Dekabank Deutsche Girozentrale owns 16,000 shares for 0.01% of their portfolio. American Century Companies Inc reported 21,169 shares stake. Fil Ltd reported 79,134 shares. State Common Retirement Fund invested 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE).

Spark Therapeutics (NASDAQ:ONCE) Rating Reaffirmed

In a note revealed to investors and clients on 8 August, The “Overweight” rating of Spark Therapeutics (NASDAQ:ONCE) shares was restate at Barclays, who now has a $77 target price on the stock. Barclays’s target price means a possible upside of 33.98 % from the last price of the company.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Coverage

Among 16 analysts covering Spark Therapeutics (NASDAQ:ONCE), 6 have Buy rating, 1 Sell and 9 Hold. Therefore 38% are positive. Spark Therapeutics has $10300 highest and $53 lowest target. $78.86’s average target is 37.22% above currents $57.47 stock price. Spark Therapeutics had 29 analyst reports since February 12, 2018 according to SRatingsIntel. As per Monday, June 25, the company rating was maintained by BMO Capital Markets. JP Morgan downgraded the shares of ONCE in report on Wednesday, February 14 to “Neutral” rating. Mizuho maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) rating on Thursday, March 29. Mizuho has “Buy” rating and $7900 target. The firm has “Buy” rating given on Tuesday, May 22 by Cantor Fitzgerald. The company was downgraded on Thursday, July 19 by RBC Capital Markets. The firm has “Buy” rating given on Wednesday, February 21 by Stifel Nicolaus. The firm has “Overweight” rating given on Wednesday, August 8 by Barclays Capital. UBS maintained the stock with “Neutral” rating in Wednesday, August 8 report. The firm has “Underperform” rating given on Tuesday, August 7 by Credit Suisse. Bernstein maintained Spark Therapeutics, Inc. (NASDAQ:ONCE) rating on Wednesday, February 21. Bernstein has “Buy” rating and $60.0 target.

The stock decreased 0.40% or $0.23 during the last trading session, reaching $57.47. About 640,756 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 41.78% since August 9, 2017 and is uptrending. It has outperformed by 29.21% the S&P500.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $2.15 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

More notable recent Spark Therapeutics, Inc. (NASDAQ:ONCE) news were published by: Nasdaq.com which released: “Mid-Day Market Update: Mallinckrodt Climbs After Q2 Beat; Gemphire Therapeutics Shares Plummet” on August 07, 2018, also Seekingalpha.com with their article: “Premarket analyst action – healthcare” published on August 08, 2018, Seekingalpha.com published: “3 Things In Biotech, August 8: Spark’s Downtrodden, Array’s Broken Through” on August 08, 2018. More interesting news about Spark Therapeutics, Inc. (NASDAQ:ONCE) were released by: Seekingalpha.com and their article: “Spark Therapeutics 2018 Q2 – Results – Earnings Call Slides” published on August 07, 2018 as well as Streetinsider.com‘s news article titled: “Pre-Open Movers 08/07: (VCEL) (MNK) (TWLO) Higher; (ONCE) (GEMP) (ZG) Lower (more…)” with publication date: August 07, 2018.

Spark Therapeutics, Inc. (NASDAQ:ONCE) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.